Salix Pharmaceuticals, Ltd. announced that it has closed the acquisition of publicly traded InKine Pharmaceutical Company, Inc. The parties signed a definitive agreement for this stock-for-stock transaction on June 23, 2005.
Wyrick Robbins has served as legal counsel to Salix since 2000, helping it raise over $135 million in equity financing, successfully defending it against a hostile takeover attempt and advising it on SEC filings and product acquisitions, among other things. During that time Salix has grown from a company with no marketed products and less than 20 employees to one with over 150 employees and six products generating over $150 million in total annualized revenue.
Our Selected Transactions pages list other transactions in which Wyrick Robbins has been involved.